Discovering potent small molecule inhibitors of cyclophilin A using de novo drug design approach

Journal of Medicinal Chemistry

Volumn 52, Issue 17, 2009, Pages 5295-5298

  Ni, Shuaishuai ^a   Yuan, Yaxia ^b   Huang, Jin ^a   Mao, Xiaona ^a   Lv, Maosheng ^a   Zhu, Jin ^a   Shen, Xu ^a,c   Pei, Jianfeng ^b   Lai, Luhua ^b   Jiang, Hualiang ^a,c   Li, Jian ^a  

^a EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b PEKING UNIVERSITY   (China)

^c SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHILIN A; CYCLOPHILIN A INHIBITOR; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; PEPTIDYLPROLYL ISOMERASE; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; BIOASSAY; CHEMICAL MODIFICATION; COMPUTER PROGRAM; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; PHARMACOPHORE; STRUCTURE ACTIVITY RELATION;

CYCLOPHILIN A; DRUG DESIGN; ENZYME INHIBITORS; INHIBITORY CONCENTRATION 50; MODELS, MOLECULAR; PROTEIN CONFORMATION; SOFTWARE;

EID: 69949084535     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9008295     Document Type: Article

References (28)

1. Galat, A. Peptidylprolyl cis/trans isomerases (immunophilins): biological diversity-targets-functions. Curr. Top. Med. Chem. 2003, 3, 1315-1347.
2. Dornan, J.; Taylor, P.; Walkinshaw, M. D. Structures of immunophilins and their ligand complexes. Curr. Top. Med. Chem. 2003, 3, 1392-1409.
3. Liu, J.; Farmer, J. D.; Lane, W. S.; Friedman, J.; Weissman, I.; Schreiber, S. L. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 1991, 66, 807-815.
4. Zou, X. J.; Matsumura, Y. J.; John, P.; Ryo, S.; Alberto, M.; Jack, M.; Stanley, C. J. Cytokine gene expression in rejecting and tolerant rat lung allograft models: analysis by RT-PCR. Transplant. Immunol. 1995, 3, 151-161.
5. Luban, J.; Bossolt, K. L.; Franke, E. K.; Kalpana, G. V.; Goff, S. P. Human immunodeficiency virus type 1 Gag protein binds to cyclophilins A and B. Cell 1993, 73, 1067-1078. (Pubitemid 23180482)
6. Luo, C.; Luo, H.; Zheng, S.; Gui, C.; Yue, L.; Yu, C.; Sun, T.; He, P.; Chen, J.; Shen, J.; Luo, X.; Li, Y.; Liu, H.; Bai, D.; Shen, J.; Yang, Y.; Li, F.; Zuo, J.; Hilgenfeld, R.; Pei, G.; Chen, K.; Shen, X.; Jiang, H. Nucleocapsid protein of SARS coronavirus tightly binds to human cyclophilin A. Biochem. Biophys. Res. Commun. 2004, 321, 557-565.
7. Capano, M.; Virji, S.; Crompton, M. Actopaxin is phosphorylated during mitosis and is a substrate for cyclin B1/cdc2 kinase. Biochem. J. 2002, 363, 29-36.
8. Dawson, T. M.; Steiner, J. P.; Lyons, W. E.; Fotuhi, M.; Blue, M.; Snyder, S. H. The immunophilins, FK506 binding protein and cyclophilin, are discretelylocalized in the brain: relationship to calcineurin. Neuroscience 1994, 62, 569-580. (Pubitemid 2141940)
9. Choi, K. J.; Piao, Y.; Lim, M.; Kim, J.; Ha, J.; Choe, W.; Kim, S. Overexpressed cyclophilin A in cancer cells renders resistance to hypoxia- and cisplatin-induced cell death. Cancer Res. 2007, 67, 3654-3662. (Pubitemid 46762150)
10. Handschumacher, R. E.; Harding, M. W.; Rice, J.; Drugge, R. J.; Speicher, D. W. Cyclophilin: a specific cytosolic binding protein for cyclosporin A. Science 1984, 226, 544-547. (Pubitemid 14018525)
11. Siekierka, J. J.; Hung, S. H.; Poe, M.; Lin, C. S.; Sigal, N. H. A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin. Nature 1989, 341, 755-757.
12. Clane, R. Y.; Lim, S.; Samaan, A.; Collier, D. S.; Pollard, S. G.; White, D. J. G.; Thiru, S. Rapamycin for immunosuppression in organ allografting. Lancet 1989, 334, 227.
13. Sedrani, R.; Kallen, J.; Martin Cabrejas, L. M.; Papageorgiou, C. D.; Senia, F.; Rohrbach, S.; Wagner, D.; Thai, B.; Jutzi Eme, A. M.; France, J.; Oberer, L.; Rihs, G.; Zenke, G.; Wagner, J. Sanglifehrin-cyclophilin interaction: Degradation work, synthetic macrocyclic analogues, X-ray crystal structure, and binding data. J. Am. Chem. Soc. 2003, 125, 3849-3859.
14. Li, Q.; Moutiez, M.; Charbonnier, J. B.; Vaudry, K.; Menez, A.; Quemeneur, E.; Dugave, C. Design of a gag pentapeptide analogue that binds human cyclophilin A more efficiently than the entire capsid protein: New insights for the development of novel anti-HIV-1 drugs. J. Med. Chem. 2000, 43, 1770-1779.
15. Li, J.; Chen, J.; Gui, C.; Zhang, L.; Qin, Y.; Xu, Q.; Zhang, J.; Liu, H.; Shen, X.; Jiang, H. Discovering novel chemical inhibitors of human cyclophilin A: virtual screening, synthesis, and bioassay. Bioorg. Med. Chem. 2006, 14, 2209-2224.
16. Li, J.; Chen, J.; Zhang, L.; Wang, F.; Gui, C.; Zhang, L.; Qin, Y.; Xu, Q.; Liu, H.; Nan, F.; Shen, J.; Bai, D.; Chen, K.; Shen, X.; Jiang, H. One novel quinoxaline derivative as a potent human cyclophilin A inhibitor shows highly inhibitory activity against mouse spleen cell proliferation. Bioorg. Med. Chem. 2006, 14, 5527-5534.
17. Li, J.; Zhang, J.; Chen, J.; Luo, X.; Zhu, W.; Shen, J.; Liu, H.; Shen, X.; Jiang, H. Strategy for discovering chemical inhibitors of human cyclophilin A: focused library design, virtual screening, chemical synthesis and bioassay. J. Comb. Chem. 2006, 8, 326-337.
18. Wang, F.; Chen, J.; Liu, X.; Shen, X.; He, X.; Jiang, H.; Bai, D. Synthesis and peptidyl-prolyl isomerase inhibitory activity of quinoxalines as ligands of cyclophilin A. Chem. Pharm. Bull. 2006, 54, 372-376.
19. Wu, Y.; Belyakov, S.; Choi, C.; Limburg, D.; Thomas, B. E., IV; Vaal, M.; Wei, L.; Wilkinson, D. E.; Holmes, A.; Fuller, M.; McCormick, J.; Connolly, M.; Moeller, T.; Steiner, J.; Hamilton, G. S. Synthesis and biological evaluation of non-peptidic cyclophilin ligands. J. Med. Chem. 2003, 46, 1112-1115.
20. Guichou, J. F.; Viaud, J.; Mettling, C.; Subra, G.; Lin, Y. L.; Chavanieu, A. Structure-based design, synthesis, and biological evaluation of novel inhibitors of human cyclophilin A. J. Med. Chem. 2006, 49, 900-910.
21. Wang, R.; Gao, Y.; Lai, L. LigBuilder: a multiple-purpose program for structure-based drug design. J. Mol. Model. 2000, 6, 498-516.
22. Fan, F.; Zhu, J.; Ni, S.; Cheng, J.; Tang, Y.; Kang, C.; Li, J.; Jiang, H. Pharmacophore refinement and 3D-QSAR studies of inhibitors of cyclophilin A containing amide linker. QSAR Comb. Sci. 2009, 28, 183-193.
23. Kofron, J. L.; Kuzmic, P.; Kishore, V.; Colon-Bonilla, E.; Rich, D. H. Determination of kinetic constants for peptidyl prolyl cis-trans isomerases by an improved spectrophotometric assay. Biochemistry 1991, 30, 6127-6134.
24. Goodsell, D. S.; Morris, G. M.; Olson, A. J. Automated docking of flexible ligands: applications of AutoDock. J. Mol. Recognit. 1996, 9, 1-5.
25. Chen, J.; Lai, L. H. Pocket v.2: Further developments on receptor-based pharmacophore modeling. J. Chem. Inf. Model. 2006, 46, 2684-2691.
26. Schneider, G.; Fechner, U. Computer based de novo design of drug-like molecules. Nature Rev. Drug Discovery 2005, 4, 649-663. (Pubitemid 41149759)
27. Schneider, G.; Hartenfeller, M.; Reutlinger, M.; Tanrikulu, Y.; Proschak, E.; Schneider, P. Voyages to the (un)known: adaptive design of bioactive compounds. Trends Biotechnol. 2009, 27, 18-26.
28. Mauser, H.; Guba, W. Recent developments in de novo design and scaffold hopping. Curr. Opin. Drug Discovery Dev. 2008, 11, 365-374.